282 related articles for article (PubMed ID: 16818183)
1. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
4. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
5. [Small cell carcinoma of the prostate: a case report].
Hashine K; Nakatsuji H; Karashima T; Sumiyoshi Y; Mandai K; Hata A
Hinyokika Kiyo; 1998 Aug; 44(8):607-10. PubMed ID: 9783201
[TBL] [Abstract][Full Text] [Related]
6. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
7. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
9. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
10. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
11. Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
[TBL] [Abstract][Full Text] [Related]
12. [Small cell carcinoma of the prostate: a case report].
Sakai H; Tsuruta T; Wajiki M
Hinyokika Kiyo; 2004 Apr; 50(4):269-71. PubMed ID: 15188622
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
14. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
15. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
16. [Small cell carcinoma of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report].
Ishizu K; Tsushimi M; Shimajiri S; Hamada T; Sasaguri Y; Naito K
Hinyokika Kiyo; 2002 Feb; 48(2):97-100. PubMed ID: 11968736
[TBL] [Abstract][Full Text] [Related]
17. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
18. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
19. Advanced prostate cancer with normal serum prostate-specific antigen values.
Cohen RJ; Haffejee Z; Steele GS; Nayler SJ
Arch Pathol Lab Med; 1994 Nov; 118(11):1123-6. PubMed ID: 7526818
[TBL] [Abstract][Full Text] [Related]
20. Gastrin-releasing peptide: predictor of castration-resistant prostate cancer?
Heinrich E; Probst K; Michel MS; Trojan L
Prostate; 2011 May; 71(6):642-8. PubMed ID: 20945407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]